Emerson Electric
EMR
$157.60
-0.11%
Emerson Electric Co. is a global industrial automation leader that designs and manufactures a wide range of automation software, power tools, and hardware such as valves, gauges, and switches, serving industries like manufacturing, energy, and chemicals. The company has transformed itself into a pure-play automation player by divesting its climate technology and consumer businesses, positioning it as a key beneficiary of the long-term trend toward factory automation and digital transformation. Currently, investor attention is focused on Emerson's ability to sustain growth through its software and systems segment, margin expansion from operational efficiencies, and the successful integration of recent acquisitions, while navigating a mixed macroeconomic environment for industrial spending.…
EMR
Emerson Electric
$157.60
Investment Opinion: Should I buy EMR Today?
We rate EMR as a Hold. The stock offers a balanced risk/reward with a modest upside to the average analyst target of $170.44 (4.5% upside). The thesis is that Emerson's automation focus and strong margins provide a stable foundation, but the current valuation limits upside potential.
Sign up to view all
EMR 12-Month Price Forecast
The AI assessment is neutral, reflecting a balanced outlook. Emerson's strong profitability and strategic positioning are offset by modest growth and a rich valuation. The stock is likely to perform in line with the market over the next 12 months, with a slight upside bias. An upgrade to bullish would require evidence of accelerating revenue growth above 5% or a meaningful margin expansion, while a downgrade to bearish would be triggered by a deterioration in industrial demand or a significant earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $171.07 and implied upside of +8.6% versus the current price.
Average Target
$171.07
0 analysts
Implied Upside
+8.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $205
Analyst target range
The wide range between the low and high targets ($104 to $205) reflects significant uncertainty about Emerson's future performance. The high target likely assumes successful execution of its automation growth strategy, further margin expansion, and a favorable industrial cycle, while the low target may price in a potential recession, competitive pressures, or integration risks. Recent rating actions have been mixed: Deutsche Bank downgraded from Buy to Hold in February 2026, while Citigroup and Evercore ISI maintained Buy/Outperform ratings. The lack of recent upgrades or downgrades in the last few months suggests that analysts are in a wait-and-see mode, awaiting more evidence of growth sustainability. Overall, the consensus is cautiously optimistic, with a modest upside to the average target.
Bulls vs Bears: EMR Investment Factors
Emerson presents a balanced risk/reward profile. The bull case is supported by strong momentum, solid profitability, and a strategic pivot to automation, while the bear case highlights modest growth and a rich valuation. Currently, the evidence slightly favors the bulls due to the company's market leadership and forward-looking growth prospects, but the narrow upside to the average target suggests limited near-term appreciation. The key tension is whether Emerson can accelerate revenue growth to justify its forward PE of 22.56x; if growth remains in the low single digits, the stock could face de-rating, whereas successful execution of its automation strategy could drive earnings upside.
Bullish
- Strong 1-Year Momentum: EMR is up 21.43% over the past year, trading at $163.17, near its 52-week high of $166.35. This outperformance versus the S&P 500 (relative strength 1.06) signals robust investor confidence and a strong uptrend.
- Healthy Profitability Metrics: The company boasts a gross margin of 52.8% and an operating margin of 19.6%, reflecting efficient operations and pricing power. Net margin stands at 12.7%, demonstrating solid bottom-line conversion.
- Attractive Forward Valuation: With a forward PE of 22.56x versus a trailing PE of 32.23x, the market expects significant earnings growth. The PEG ratio of 1.78x suggests the stock is reasonably priced relative to its growth prospects.
- Positive Analyst Sentiment: The consensus recommendation is 'Buy' with an average target price of $170.44, implying a modest 4.5% upside from the current price. 27 analysts cover the stock, indicating strong institutional interest.
Bearish
- High Valuation Relative to Growth: The trailing PE of 32.23x is elevated for a company with only 2.93% revenue growth in the latest quarter. This implies the market is pricing in a significant acceleration that may not materialize.
- Modest Revenue Growth: Revenue growth has been in the low single digits, with Q2 FY2026 revenue of $4.562 billion, up just 2.93% YoY. This is below the pace typically expected for a growth-oriented industrial.
- Potential Overextension Near Highs: Trading at 98.1% of its 52-week range, the stock may be vulnerable to a pullback. The recent 1-month gain of 19.76% suggests short-term overbought conditions.
- Mixed Analyst Actions: Deutsche Bank downgraded EMR from Buy to Hold in February 2026, reflecting concerns about growth sustainability. While other firms maintain Buy ratings, the downgrade highlights uncertainty.
EMR Technical Analysis
Emerson's stock is in a strong uptrend, with a 1-year price change of +21.43% and currently trading at $163.17, which is 98.1% of its 52-week range (low $122.64, high $166.35). This positioning near the highs indicates robust momentum and investor confidence, though it also raises the risk of short-term overextension. The stock has outperformed the S&P 500 over the past year (relative strength 1.06), confirming its leadership within the industrial sector.
Beta
1.24
1.24x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$166
Price range past year
Annual Return
+19.8%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +15.4% | +3.6% |
| 3m | +16.8% | +3.5% |
| 6m | +6.0% | +11.6% |
| 1y | +19.8% | +20.2% |
| ytd | +16.0% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Emerson's revenue growth has been steady but modest, with the most recent quarter (Q2 FY2026, ending March 31, 2026) showing revenue of $4.562 billion, up 2.93% year-over-year. This follows a pattern of low single-digit growth over the past several quarters: Q1 FY2026 revenue was $4.346 billion, Q4 FY2025 was $4.855 billion, and Q3 FY2025 was $4.553 billion. The growth is driven primarily by the Software and Systems segment, which contributed $1.503 billion in the latest quarter, while Intelligent Devices remains the largest segment at $2.512 billion. The company is not experiencing explosive growth, but it is maintaining a stable trajectory, which is typical for a mature industrial automation player.
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
53.1%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Given that Emerson has positive net income, the PE ratio is the most appropriate valuation metric. The trailing PE is 32.23x, while the forward PE is 22.56x, indicating that the market expects significant earnings growth in the coming year. This forward discount of ~30% suggests that analysts anticipate a strong earnings acceleration, likely driven by margin expansion and cost synergies from recent acquisitions. The PEG ratio of 1.78x implies that the stock is not excessively overvalued relative to its expected growth rate, though it is not a deep value either.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.68, indicating moderate leverage, and a current ratio of 0.88, suggesting potential liquidity constraints. The company's net margin of 12.7% is healthy, but any margin compression from input costs or integration issues could pressure earnings. Additionally, the reliance on continued growth to justify the forward PE of 22.56x means that any earnings miss could lead to a sharp multiple contraction.
FAQ
The key risks include: 1) Valuation risk - the trailing PE of 32.23x could compress if growth slows. 2) Macro risk - a recession could reduce industrial spending, impacting revenue. 3) Competitive risk - increased competition in automation could pressure margins. 4) Financial risk - the debt-to-equity ratio of 0.68 and current ratio of 0.88 indicate leverage and liquidity concerns. The most severe risk is a -24.9% drop to the 52-week low of $122.64.
The 12-month forecast is moderately positive. The base case (55% probability) targets $160-$175, with the average analyst target at $170.44. The bull case (25% probability) could reach $180-$205, while the bear case (20% probability) could fall to $120-$140. The most likely scenario is a modest gain, driven by steady growth and stable margins.
EMR is fairly valued relative to its growth prospects, with a forward PE of 22.56x and a PEG ratio of 1.78x. However, compared to the broader market, it trades at a premium, reflecting its quality and automation exposure. The market expects earnings growth of about 30% over the next year, which is optimistic given the recent revenue growth of only 2.93%. If growth disappoints, the stock could de-rate.
EMR is a good buy for investors with a long-term horizon who value stability and income. The stock offers a dividend yield of 1.61% and a modest upside to the average analyst target of $170.44 (4.5%). However, the trailing PE of 32.23x is high, and the stock is near its 52-week high, so there is limited margin of safety. It is best to buy on pullbacks, especially if the price drops below $150.
EMR is more suitable for long-term investment due to its stable business model, dividend yield, and exposure to secular automation trends. The beta of 1.235 indicates moderate volatility, making it less ideal for short-term trading. A minimum holding period of 3-5 years is recommended to ride out cyclical downturns and benefit from the automation growth story.